{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:06:40Z","timestamp":1786133200743,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"Juvenile Diabetes Research Foundation","award":["3-SRA-2022-1244-M-B"],"award-info":[{"award-number":["3-SRA-2022-1244-M-B"]}]},{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"crossref","award":["K23DK118197"],"award-info":[{"award-number":["K23DK118197"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"crossref","award":["K24DK110427"],"award-info":[{"award-number":["K24DK110427"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2025,3]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Low-dose acetazolamide reversibly lowered GFR in persons with type 1 diabetes mellitus, suggesting a possible role in relieving glomerular hyperfiltration.<\/jats:p>\n <\/jats:list-item>\n \n Low doses of acetazolamide were well tolerated in persons with type 1 diabetes.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Sodium-glucose cotransporter-2 inhibitors (SGLT2is) lower the risk of kidney failure in persons with type 2 diabetes. The presumed mechanism of action is through greater delivery of sodium to the distal tubule and activation of tubuloglomerular feedback, which lowers GFR and intraglomerular pressure. SGLT2is are not approved for use in persons with type 1 diabetes because of the risk of diabetic ketoacidosis. Acetazolamide, a proximal tubule diuretic, delivers more sodium to the distal nephron and may activate tubuloglomerular feedback in a similar way to SGLT2is without a higher risk of diabetic ketoacidosis. The kidney effects and safety of acetazolamide in persons with type 1 diabetes have not been well studied.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a dose-escalation trial to determine the effects of three dosages of oral acetazolamide (62.5, 125, and 250 mg, all twice daily) in 12 persons with type 1 diabetes. Participants were treated for 2 weeks, followed by a 2-week washout period before exposure to the next dosage level. Blood and urine chemistries, as well as iohexol-measured GFR, were assessed before and after each treatment interval. We aimed to identify a dose that maximized measured GFR reductions while minimizing adverse effects.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The mean age was 46\u00b117 years, 100% were White, and 75% were female. The mean measured GFR was 89\u00b118 ml\/min per 1.73 m\n 2<\/jats:sup>\n at baseline. Acetazolamide reduced measured GFR by 15% (95% confidence interval [CI], 9 to 21), 14% (95% CI, 7 to 21), and 15% (95% CI, 10 to 21) after 2 weeks at the 62.5, 125, and 250 mg twice-daily dosage levels, respectively. The measured GFR reduction was fully reversed after each 2-week washout. Serum bicarbonate was reduced by 2.3, 4.2, and 4.4 mEq\/L with escalating doses, and no episodes of hypokalemia (<3.5 mEq\/L) were observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Among persons with type 1 diabetes and preserved kidney function, acetazolamide caused an acute, reversible reduction in measured GFR without effects on glucose metabolism.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number:<\/jats:title>\n Acetazolamide in Persons with Type 1 Diabetes, NCT05473364.<\/jats:p>\n <\/jats:sec>\n \n Podcast<\/jats:title>\n This article contains a podcast at https:\/\/dts.podtrac.com\/redirect.mp3\/www.asn-online.org\/media\/podcast\/JASN\/2024_12_23_ASN0000000515.mp3<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000000515","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:24:25Z","timestamp":1728390265000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Acetazolamide Therapy and Kidney Function in Persons with Nonalbuminuric Diabetes Mellitus Type 1"],"prefix":"10.1681","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9408-3684","authenticated-orcid":false,"given":"Charles","family":"Ginsberg","sequence":"first","affiliation":[{"name":"Division of Nephrology-Hypertension, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-6502","authenticated-orcid":false,"given":"Jesse C.","family":"Seegmiller","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Vallon","sequence":"additional","affiliation":[{"name":"Division of Nephrology-Hypertension, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5832-4026","authenticated-orcid":false,"given":"Sami","family":"SeungMi Jin","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-5013","authenticated-orcid":false,"given":"Robert L.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Endocrinology Section, Veterans Affairs San Diego Healthcare System, San Diego, California"},{"name":"Division of Endocrinology and Metabolism, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6221-7796","authenticated-orcid":false,"given":"Schafer C.","family":"Boeder","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Pettus","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, University of California, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9869","authenticated-orcid":false,"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[{"name":"Division of Nephrology-Hypertension, University of California, San Diego, California"},{"name":"Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"14","key":"B1-20250303","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.294.14.1782","article-title":"Incidence of end-stage renal disease in patients with type 1 diabetes","volume":"294","author":"Finne","year":"2005","journal-title":"JAMA."},{"issue":"3","key":"B2-20250303","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc17-2364","article-title":"Incidence of end-stage renal disease in patients with type 1 diabetes","volume":"41","author":"Helve","year":"2018","journal-title":"Diabetes Care."},{"issue":"1","key":"B3-20250303","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1748-1716.2010.02147.x","article-title":"Tubular reabsorption and diabetes-induced glomerular hyperfiltration","volume":"200","author":"Persson","year":"2010","journal-title":"Acta Physiol (Oxf)."},{"issue":"25","key":"B4-20250303","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med."},{"issue":"20","key":"B5-20250303","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The collaborative study group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med."},{"issue":"12","key":"B6-20250303","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"issue":"4","key":"B7-20250303","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"issue":"24","key":"B8-20250303","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"12","key":"B9-20250303","doi-asserted-by":"crossref","first-page":"e1003461","DOI":"10.1371\/journal.pmed.1003461","article-title":"Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression","volume":"17","author":"Musso","year":"2020","journal-title":"PLoS Med."},{"issue":"6","key":"B10-20250303","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol."},{"issue":"1","key":"B11-20250303","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes."},{"issue":"2","key":"B12-20250303","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia."},{"issue":"5","key":"B13-20250303","doi-asserted-by":"crossref","first-page":"F761","DOI":"10.1152\/ajprenal.00552.2020","article-title":"Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats","volume":"320","author":"Thomson","year":"2021","journal-title":"Am J Physiol Renal Physiol."},{"issue":"6","key":"B15-20250303","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00424-004-1330-1","article-title":"Effect of carbonic anhydrase inhibition on GFR and renal hemodynamics in adenosine-1 receptor-deficient mice","volume":"448","author":"Hashimoto","year":"2004","journal-title":"Pflugers Arch."},{"issue":"9","key":"B16-20250303","doi-asserted-by":"crossref","first-page":"e0137163","DOI":"10.1371\/journal.pone.0137163","article-title":"Effect of acetazolamide on obesity-induced glomerular hyperfiltration: a randomized controlled trial","volume":"10","author":"Zingerman","year":"2015","journal-title":"PLoS One."},{"issue":"6","key":"B17-20250303","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/00365518909089139","article-title":"The acute effect of acetazolamide on glomerular filtration rate and proximal tubular reabsorption of sodium and water in normal man","volume":"49","author":"Sk\u00f8tt","year":"1989","journal-title":"Scand J Clin Lab Invest."},{"issue":"19","key":"B18-20250303","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"New Engl J Med."},{"key":"B19-20250303","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinbiochem.2019.03.007","article-title":"Verification of separate measurement procedures where analytical determinations influence the clinical interpretation of GFR: iohexol quantitation by HPLC and LC-MS\/MS","volume":"67","author":"Schmit","year":"2019","journal-title":"Clin Biochem."},{"issue":"3","key":"B20-20250303","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/00365517209084290","article-title":"A simple method for the determination of glomerular filtration rate","volume":"30","author":"Br\u00f6chner-Mortensen","year":"1972","journal-title":"Scand J Clin Lab Invest."},{"issue":"1","key":"B21-20250303","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med."},{"issue":"10","key":"B22-20250303","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.2013070758","article-title":"Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes","volume":"25","author":"Sabbisetti","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B23-20250303","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1042\/cs0810457","article-title":"Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients","volume":"81","author":"Hannedouche","year":"1991","journal-title":"Clin Sci."},{"issue":"1","key":"B24-20250303","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s002280050422","article-title":"Pharmacokinetics and pharmacodynamics of acetazolamide in patients with transient intraocular pressure elevation","volume":"54","author":"Yano","year":"1998","journal-title":"Eur J Clin Pharmacol."},{"issue":"2","key":"B25-20250303","doi-asserted-by":"crossref","first-page":"F419","DOI":"10.1152\/ajprenal.00497.2018","article-title":"Effect of renal tubule-specific knockdown of the Na+\/H+ exchanger NHE3 in Akita diabetic mice","volume":"317","author":"Onishi","year":"2019","journal-title":"Am J Physiol Renal Physiol."},{"issue":"4","key":"B26-20250303","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na +\/H + exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2","key":"B27-20250303","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1681\/ASN.0000000000000269","article-title":"Empagliflozin in heart failure: regional nephron sodium handling effects","volume":"35","author":"Rao","year":"2024","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B28-20250303","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF00277481","article-title":"Effects of acetazolamide on kidney function in type 1 (insulin-dependent) diabetic patients with diabetic nephropathy","volume":"31","author":"Sk\u00f8tt","year":"1988","journal-title":"Diabetologia."},{"issue":"7","key":"B29-20250303","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/dme.12717","article-title":"Glomerular haemodynamic profile of patients with type 1 diabetes compared with healthy control subjects","volume":"32","author":"\u0160krti\u0107","year":"2015","journal-title":"Diabet Med."},{"issue":"4","key":"B30-20250303","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0272-6386(04)00936-9","article-title":"Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"44","author":"Bommer","year":"2004","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B31-20250303","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1681\/ASN.0000000000000085","article-title":"Comprehensive associations between acidosis and the skeleton in patients with kidney disease","volume":"34","author":"Levy","year":"2023","journal-title":"J Am Soc Nephrol."},{"issue":"7651","key":"B32-20250303","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(70)92432-3","article-title":"Acetazolamide and renal stone formation","volume":"1","author":"Pepys","year":"1970","journal-title":"Lancet."},{"issue":"12","key":"B33-20250303","first-page":"16526","article-title":"Diuretic, natriuretic, and chloride-regaining effects of oral acetazolamide as an add-on therapy for acute heart failure with volume overload: a single-center, prospective, randomized study","volume":"133","author":"Kosiorek","year":"2023","journal-title":"Pol Arch Intern Med."},{"issue":"1","key":"B34-20250303","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"B35-20250303","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol."},{"issue":"13","key":"B36-20250303","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:30:11Z","timestamp":1786131011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000515","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"2024-06-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}